Revvity Inc. has announced a collaboration with Eli Lilly and Company to expand access to Lilly’s advanced AI drug discovery models. Through this partnership, Lilly’s predictive models, developed by its TuneLab, will be made available on Revvity’s Signals platform, including the Signals Xynthetica offering. The joint initiative aims to lower barriers to AI adoption in the biotech sector by co-funding access for selected participants and enabling organizations to securely apply Lilly’s models to their own research while keeping proprietary data private. This collaboration supports federated learning, allowing small and midsize biotechs to contribute data and collectively enhance the performance of AI-driven drug discovery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260109127353) on January 09, 2026, and is solely responsible for the information contained therein.